Numbers 3 Flashcards
Sensitivity and specificity of IOTA
95%
91%
RMI score >200 sensitivity and specificity
78%
87%
Risk chemical peritonitis in dermoid cyst spillage
0.2%
% reduction in hirsutism by weight reduction 5-10%
40-55%
% reduction in hair growth with Eflornithine
60%
% of POI who conceive
10-15%
Number of follicles by puberty
0.5 million
% POI in Fragile X Syndrome
13-26%
% POI with osteopenia
50%
Precocious puberty incidence
1:5000-10,000
% of idiopathic cause of central precocious puberty
74%
% of metabolic syndrome in women with PCOS
33%
Risk of CHD and stroke in PCOS
Risk in metabolic syndrome
2x
3-6x
Risk T2DM in PCOS + metabolic syndrome
5x
Risk OSA in PCOS
30x
Incidence of congenital uterine abnormalities
3%
90% septate uterus
5% bicornuate
5% didelphic
% of MRKH syndrome with renal tract abnormality
40%
% delayed puberty
3%
Incidence of puerperial genital haematomas
1:700
% women who choose ELCS after previous 3rd/4th degree tear
25%
Rate of postpartum psychosis
1:1000
VIN 3 progression rate
6.5%
% VIN will show invasive cancer on excision
12-17%
Risk of VIN without WLE progression to cancer in 8 years
40-60%
Risk VIN with WLE progression to cancer
4%
Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids <40yo
<1:500
Risk of leiomyosarcoma in women undergoing surgery for presumed fibroids 75-79yo
1:100
% vulval carcinoma that is SCC
90%
Risk of vulval ca recurrence if disease free margin >8mm
0%
Risk of vulval ca recurrence if disease free margin <8mm
47%
Risk of fetal loss if dysgerminoma removal in pregnancy
25%
% that adnexal mass is not ovarian
10%
% of operable vulval cancer that will have lymph node spread
30%
Prevalence of ovarian cysts in postmenopausal women
5-17%
CA125 >30 sensitivity and specificity for ovarian ca
81%
75%
IOTA sensitivity and specificity for ovarian cancer
95%
91%
RMI sensitivity and specificity for ovarian cancer
78%
87%
UK ovarian cancer complete cytoreduction %
<12%
Every 10% improvement in maximum cytoreduction improves survival by what %
5%
OC response rate in platinum resistant recurrence
10-20%
OC response rate in platinum refractory recurrence
<10%
OC response rate in platinum partially (>6/12, <12/12) sensitive recurrence
25-30%
OC response rate in platinum sensitive (>12/12) recurrence
40-75%
5yr survival Stage 1 BOT
95-97%
5yr survival Stage 3 BOT
50-86%
10yr survival BOT
70-80%
Relapse of BOT with radical treatment
2.5-5.7%
Relapse of BOT with unilateral SPO
0-20%
Relapse of BOT with cystectomy
12-58%
Incidence of invasive disease in recurrent BOTs
8-73%
Survival % for early stage germ cell tumour
90%
Survival % for advanced germ cell tumour
75-80%
% of MOGCT recurrence that occurs within 1st year
75%
5yr survival rate for Stage 4 epithelial ovarian cancer
5%
5yr survival rate for Stage 3 epithelial ovarian cancer
20%
5yr survival rate for Stage 2 epithelial ovarian cancer
40%
5yr survival rate for Stage 1 epithelial ovarian cancer
90%
Overall 5 yr survival for epithelial ovarian cancer
45%
Sporadic FH of EOC - 1 family member - risk of EOC
4-5%
Sporadic FH of EOC - 2 family members - risk of EOC
7%
Hereditary EOC - 2 first degree relatives - risk of EOC
13-50%
BRCA1 risk of ovarian cancer
35-46%
BRCA2 risk of ovarian cancer
13-23%
Lynch syndrome risk of ovarian cancer
3-14%
Peutz Jeghers risk of ovarian cancer
20%
% that risk reducing surgery (rrBSO) reduces breast cancer in BRCA carriers
30-75%
% risk of peritoneal cancer in BRCA carriers
2%
% occult malignancy in risk reducing surgery (rrBSO)
4-8%
Risk of endometrial cancer with Lynch syndrome
40-60%
% of STICs seen in prophylactic BSO for primary peritoneal disease
10-15%
% STICs in serous ovarian carcinoma
48-61% (small studies)
% that risk reducing surgery (rrBSO) can reduce ovarian/fallopian tube/peritoneal cancer in BRCA carriers
80%
% risk reduction for EOC with tubal ligation/removal
29%
% risk reduction of serous OC or primary peritoneal cancer with salpingectomy
60%
% that ovarian cancer is hereditary
10-15%
% 1st trimester miscarriage in radical trachelectomy
% 2nd trimester miscarriage
% of full term pregnancies
16-20% (similar to BG)
8-10%
70-75%
Radical trachelectomy recurrence
4.2-5.6%
% of conversion to laparotomy for lap treatment of endometrial cancer
26%
% LN involvement in cervical ca Stage 1A1
1%
% LN involvement in cervical ca Stage 1A2
5%
% cervical cancer caused by HPV 16 & 18
70-80%
% vulval and oropharyngeal cancer caused by HPV 16 & 18
40-50%
% anal cancers caused by HPV 16 & 18
70-80%
High risk HPV screen sensitivity and specificity
96%
99%
% VIN caused by HPV 16
67.5%
% VC caused by HPV 16
32.2%
5yr survival rate stage 1 endometrial cancer
85-90%
5yr survival rate stage 2 endometrial cancer
65%
5yr survival rate stage 3 endometrial cancer
45-60%
5yr survival rate stage 4 endometrial cancer
15%
% cervical cancer that are squamous
70%
Overall cervical cancer 5yr survival rate
68%
Risk a TOA in postmenopausal woman
47%
% CPP after 1 episode of TOA
12%
% CPP after 2 episodes of TOA
30%
% CPP after 3 episodes of TOA
67%
% PID is polymicrobial
30-40%
% PID due to chlamydia/gonorrhoea
25%
Cure rate of pelvic exenteration in recurrent cervical cancer
30-50%
% CIN that will regress
50%
Recurrence rate of ectopic
18%
Severe polyhydramnios
> 35cm
Moderate polyhydramnios
30-34.9cm
Mild polyhydramnios
25-29.9cm
Incidence of endometrial cancer
28:100,000
% of thecomas that are androgenic
10%
% of abnormalities on USS that are cystic hygroma
35%
% cystic hygromas associated with fetal chromosomal abnormalities
50%
